Literature DB >> 26223812

A proposal for a new classification of T4 breast cancer as stage IIIC: a report from the Korean Breast Cancer Society.

Hee Jeong Kim1, Hwa Jung Kim, Sae Byul Lee, Hyeong-Gon Moon, Woo Chul Noh, Young Up Cho, Youngbum Yoo, Sei Hyun Ahn.   

Abstract

The objective of this study is to investigate staging system of the stage IIIB and stage IIIC Breast cancer and determine the criteria for an update of the classification system. Since AJCC 6th edition, it is pointed out that stage IIIB showed a worse outcome compared with stage IIIC. Using information from two databases, including the nationwide Korean Breast Cancer Registry (KBCR), three cohorts composed of patients from the Asan Medical Center from 1989 to 2002 (cohort I), from 2003 to 2008 (cohort II), and KBCR from 2003 to 2005 (cohort III) were assembled. New classifications were suggested that rearranged stage IIIB as T1-3N3 disease and stage IIIC as T4 any N disease. From the joint analysis of 9640, invasive breast cancer patients from cohorts I and II showed the stage IIIB group showed a significantly worse DFS (HR 10.4, 95% CI 6.9-15.7) compared with the stage IIIC group (HR 7.2, 95% CI 5.9-8.7). T4d breast cancer showed worse DFS than T4 abc breast cancer but not significant (p = 0.505). The survival of patients with T1N3 and T2N3 tumors was higher than the other groups, and patients with T4N3 tumors showed the worst survival outcomes in terms of DFS, CSS. Using new suggested classification, in cohort III, the stage IIIB HR for CSS was changed from 15.4 (95% CI 10.6-22.1) in the AJCC 6th edition to 12.6 (95% CI 10.1-15.6) in the proposed new staging system. The stage IIIC HR for CSS was changed from 13.3 (95% CI 10.7-16.4) in the AJCC 6th edition to 18.9 (95% CI 14.0-25.6) in the proposed new staging using stage I as a reference. Reclassification of T4 any N disease as stage IIIC and T1-3N3 disease as stage IIIB is appropriate.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26223812     DOI: 10.1007/s10549-015-3501-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  2 in total

1.  Screening Hub Genes of Hepatocellular Carcinoma Based on Public Databases.

Authors:  Shan Gao; Dongjie Zhu; Jian Zhu; Lianqiang Shen; Ming Zhu; Xuefeng Ren
Journal:  Comput Math Methods Med       Date:  2021-10-26       Impact factor: 2.238

2.  A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer.

Authors:  Sae Byul Lee; Guiyun Sohn; Jisun Kim; Il Yong Chung; Jong Won Lee; Hee Jeong Kim; Beom Seok Ko; Byung Ho Son; Sei-Hyun Ahn
Journal:  Breast Cancer Res Treat       Date:  2018-01-31       Impact factor: 4.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.